New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...

REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...

Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...

As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing ...

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...

OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about ...

Vonaprument reduced the proportion of eyes with clinically meaningful vision loss, though not uniformly across doses. Through ...

Published online in April in JAMA Ophthalmology, the phase 3 CONDOR trial (NCT04278417) found that brolucizumab (Beovu; ...